Who are Oxabact OC5 - Oxalobacter formigenes HC-1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): INF108F probiotic, Lactobacillus casei variety rhamnosus granules, lactobacillus LB, E. coli Nissle suspension, Lactobacillus Crispatus M247, lactobacillus LS.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oxabact-oc5-oxalobacter-formigenes-hc-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Oxabact OC5 - Oxalobacter formigenes HC-1 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oxabact OC5 - Oxalobacter formigenes HC-1 (Oxabact OC5 - Oxalobacter formigenes HC-1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live biotherapeutic product. Area: Nephrology.

phase 3 Live biotherapeutic product Nephrology Biologic Live · refreshed every 30 min

Target snapshot

Oxabact OC5 - Oxalobacter formigenes HC-1 (Oxabact OC5 - Oxalobacter formigenes HC-1) — OxThera. Oxabact OC5 is a live biotherapeutic product that works by colonizing the gut with Oxalobacter formigenes HC-1, which degrades oxalate, reducing its absorption and systemic levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Oxabact OC5 - Oxalobacter formigenes HC-1 TARGET	Oxabact OC5 - Oxalobacter formigenes HC-1	OxThera	phase 3	Live biotherapeutic product
INF108F probiotic	INF108F probiotic	Massachusetts General Hospital	marketed	Live biotherapeutic product (probiotic)
Lactobacillus casei variety rhamnosus granules	Lactobacillus casei variety rhamnosus granules	Seoul National University Hospital	marketed	Probiotic / Live biotherapeutic product
lactobacillus LB	lactobacillus LB	Hospital General de Mexico	marketed	Live biotherapeutic product / Probiotic
E. coli Nissle suspension	E. coli Nissle suspension	University of Hohenheim	marketed	Live biotherapeutic product (probiotic)
Lactobacillus Crispatus M247	Lactobacillus Crispatus M247	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	Live biotherapeutic product
lactobacillus LS	lactobacillus LS	Ain Shams University	phase 3	Live biotherapeutic product / Probiotic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live biotherapeutic product class)

Ardeypharm GmbH · 1 drug in this class
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 drug in this class
Infant Bacterial Therapeutics · 1 drug in this class
Mikrobiomik Healthcare Company S.L. · 1 drug in this class
OxThera · 1 drug in this class
Rebiotix Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oxabact OC5 - Oxalobacter formigenes HC-1 — Competitive Intelligence Brief. https://druglandscape.com/ci/oxabact-oc5-oxalobacter-formigenes-hc-1. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab